Diagnosis of Early-Onset Colorectal Cancer Often Delayed
By Lori Solomon HealthDay Reporter
WEDNESDAY, May 29, 2024 -- Nearly half of individuals diagnosed with early-onset colorectal cancer (EOCRC) present with hematochezia and abdominal pain, and one-quarter present with altered bowel habits, according to a review published online May 24 in JAMA Network Open.
Joshua Demb, Ph.D., from the University of California, San Diego, and colleagues examined the most common presenting signs and symptoms with EOCRC (<50 years), their association with EOCRC risk, and time from presentation to diagnosis.
Based on 81 studies (>24.9 million patients), the researchers found that the most common presenting signs and symptoms included hematochezia (pooled prevalence, 45 percent), abdominal pain (pooled prevalence, 40 percent), and altered bowel habits (pooled prevalence, 27 percent). Higher EOCRC likelihood was associated with hematochezia (estimate range, 5.2 to 54.0), abdominal pain (estimate range, 1.3 to 6.0), and anemia (estimate range, 2.1 to 10.8). A mean of 6.4 months was seen from time from signs and symptoms presentation to EOCRC diagnosis (median four months).
"These findings and the increasing risk of CRC in individuals younger than 50 years highlight the urgent need to educate clinicians and patients about these signs and symptoms to ensure that diagnostic workup and resolution are not delayed," the authors write. "Adapting current clinical practice to identify and address these signs and symptoms through careful clinical triage and follow-up could help limit morbidity and mortality associated with EOCRC."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
NCCN: Cancer Drug Shortages Remain a Challenge for Clinicians
FRIDAY, June 28, 2024 -- Almost 90 percent of medical centers report cancer drug shortages, which often impact clinical trials, according to the results of a National...
PIK3CA Could Guide Use of COX-2 Inhibitors in Treatment for Colon Cancer
THURSDAY, June 27, 2024 -- PIK3CA mutational status may be beneficial for predicting response to addition of the cyclooxygenase 2 (COX-2) inhibitor celecoxib to standard adjuvant...
Neoadjuvant Nivolumab, Ipilimumab Safe for dMMR Colon Cancer
WEDNESDAY, June 5, 2024 -- Neoadjuvant nivolumab plus ipilimumab has an acceptable safety profile in patients with locally advanced mismatch repair-deficient (dMMR) colon cancer...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.